METHOTREXATE 10mg. IP

The disease-modifying antirheumatic drug helps treat rheumatoid arthritis and psoriatic arthritis by interrupting the processes of the immune system that cause inflammation in the joint tissues. An antirheumatic drug that alleviates symptoms, attenuates disease activity and prevents the progression of the disease. (Tom D Wilsdon, 2019) Reduces the risk of uncontrolled inflammation causing long-term damage to joints. A potent therapeutic option for the treatment of rheumatoid arthritis and other rheumatic diseases. (Edwin S L Chan, 2010) Exerts immunomodulatory and anti-inflammatory actions and significantly improves a wide range of health-related quality of patient’s life. (Giovanna Ferrara, 2018) Slows the natural course of the disease, reduces joint damage and pain, and retards loss of function and disability. (Theresa Kapral, 2006) Reduces the inflammation, pain, swelling, redness, morning stiffness, and other symptoms associated with rheumatoid arthritis. A safe and efficacious medication in the management of rheumatoid arthritis and psoriasis arthritis. (Musaab Elmamoun, 2018) Diminishes inflammation in the joint by diminishing cytokine production. (Cronstein, 2002) The most effective disease-modifying antirheumatic drug for the treatment of rheumatoid arthritis. (Cronstein, 2002) An efficacious agent for the treatment of refractory rheumatoid arthritis. (R N Thompson, 1984) A valuable therapeutic option in patients in whom other therapies, especially biologicals, cannot be used or have proven insufficiently effective. (Theresa Kapral, 2006) A potential candidate the significantly reduces progression of joint damage. (Maria Angeles Lopez‐Olivo, 2014) An effective therapeutic drug for inflammatory arthritis in patients who do not respond to therapy with nonsteroidal anti-inflammatory drugs or slow-acting antirheumatic drugs. (L E Boh, 1986) An effective treatment for children with resistant juvenile rheumatoid arthritis. (E H Giannini, 1992)